# US 2006/0014689 A1 · Method of Treatment of Cancer Using Guanosine 3', 5' Cyclic Monophosphate (Cyclic GMP)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0014689 A1
- Document ID: US20060014689A1
- Status: Published application
- Kind: A1
- Application number: 11/162,056
- Filed: 2005-08-26
- Published: 2006-01-19
- Earliest claimed: 2004-03-18
- Assignees: University of South Florida
- Inventors: David Vesely
- Web page: https://patentgrep.com/patent/US20060014689A1

## CPC

- A61K 38/2242: {Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- Y10S 930/05: Atrial or brain natriuretic peptide; related peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.

## Claims

### Claim 1

A method of modulating the growth of cancer cells comprising the step of contacting at least one target cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone.

### Claim 2 (depends on 1)

The method of claim 1 where the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kaliuretic peptide.

### Claim 3 (depends on 1)

The method of claim 1 wherein the intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of cyclic GMP and cell permeable analogs thereof.

### Claim 4 (depends on 1)

The method of claim 1 wherein the target cell is selected from the group consisting of adenocarcinomas, sarcomas, small-cell carcinomas and squamous cell carcinoma.

### Claim 5 (depends on 1)

The method of claim 1 wherein the effective amount of peptide hormone is administered to at least one target cell in vivo.

### Claim 6

A method of inhibiting the growth of cancer cells comprising the steps of: contacting at least one target cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone; and co-administering an effective amount of at least one peptide hormone derived from the atrial natriuretic peptide prohormone.

### Claim 7 (depends on 6)

The method of claim 6 where the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kaliuretic peptide.

### Claim 8 (depends on 6)

The method of claim 6 wherein the intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of cyclic GMP and cell permeable analogs thereof.

### Claim 9 (depends on 6)

The method of claim 6 wherein the target cell is an adenocarcinoma, sarcoma, small-cell or squamous cell carcinoma.

### Claim 10 (depends on 6)

The method of claim 6 wherein the effective amount of the combination of the intracellular mediator and the peptide hormone is administered to at least one target cell in vivo.

### Claim 11

A method of inhibiting the growth of cancer cells comprising the steps of: contacting at least one target cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone; and co-administering an effective amount of a peptide hormone derived from the atrial natriuretic peptide prohormone, wherein the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kaliuretic peptide, where the target cell is selected from the group consisting of adenocarcinomas, sarcomas, small cell and squamous cell carcinoma, and the effective amount of peptide hormone is administered in vivo.

### Claim 12 (depends on 11)

The method of claim 11 wherein the intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone is cyclic GMP, or a cell permeable analog thereof.

### Claim 13

A method of inhibiting the growth of cancer cells comprising the steps of: contacting at least one target cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone; and co-administering an effective amount of a combination of peptide hormones derived from the atrial natriuretic peptide prohormone, wherein the combination of peptide hormones derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator, and kaliuretic peptide, where the target cell is chosen from the group consisting of adenocarcinoma, small cell and squamous cell carcinoma, and the effective amount of the combination of peptide hormones is administered in vivo.

### Claim 14 (depends on 13)

The method of claim 13 wherein the intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of cyclic GMP and cell permeable analogs thereof.
